IHC 2021 | Rimegepant for migraine: rapid onset of preventive treatment effects

Christopher Jensen, PharmD, MBA, Biohaven Pharmaceuticals, New Haven, CT, describes the implications of the findings from the post-hoc analysis of the Phase II/III, randomized, double-blind, placebo-controlled trial (NCT03732638) that evaluated the safety and efficacy of rimegepant as a preventive treatment for migraine in adults. The results showed that the onset of preventive treatment effects is relatively rapid with oral rimegepant, which is new for preventive migraine treatments since other options can take weeks or months. As rimegepant is also effective in the acute treatment of migraine, it is an option that offers flexibility and the ability to create individualized treatment depending on the patient’s needs. This interview took place during the International Headache Congress 2021.